TGTX TG Therapeutics
TG Therapeutics earnings company data as of 10:00 AM ET 10/23
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 2 Nov | EPS | 0.36 | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by TGTX's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $438K sold by 2 insiders outside a trading plan
- None no planned (10b5-1) sales
-
Laurence N Charney DirectorSale$275K 5,000 shares at $54.96 2.9% of stakeTraded Sep 10 Filed Sep 14
-
Yann Echelard DirectorSale$163K 5,000 shares at $32.57 2.2% of stakeTraded Nov 24, 2025 Filed Nov 25, 2025
Also filed in the last 12 months, not counted as buying or selling: 7 gifts and 2 stock grants.
SEC filings
Recent issuer filings from EDGAR, 22 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 10-Q | FORM 10-Q | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | FORM 10-Q | Filing Doc | |
| DEF 14A | FORM DEF 14A | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 1.01,2.03,9.01 | Filing Doc | |
| 10-K | FORM 10-K | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | FORM 10-Q | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | FORM 10-Q | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 5.07,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 10-Q | FORM 10-Q | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.